about
Enabling miniaturised personalised diagnostics: from lab-on-a-chip to lab-in-a-drop.Residual Ammonium Persulfate in Nanoparticles Has Cytotoxic Effects on Cells through Epithelial-Mesenchymal Transition.Rapid, ultra low coverage copy number profiling of cell-free DNA as a precision oncology screening strategy.Circulating cell-free DNA and circulating tumor cells, the "liquid biopsies" in ovarian cancer.HCMDB: the human cancer metastasis database.Exome and transcriptome sequencing identifies loss of PDLIM2 in metastatic colorectal cancers.Zinc-Modified Nanotransporter of Doxorubicin for Targeted Prostate Cancer Delivery.The changing face of clinical trials in the personalized medicine and immuno-oncology era: report from the international congress on clinical trials in Oncology & Hemato-Oncology (ICTO 2017).Dualistic Role of BARD1 in Cancer.Using single-cell multiple omics approaches to resolve tumor heterogeneity.Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology.Loss of Capicua alters early T cell development and predisposes mice to T cell lymphoblastic leukemia/lymphoma.Neutrophils and anti-cancer immunity: a paradigm shift in cancer immunotherapy.A novel genomic signature predicting FDG uptake in diverse metastatic tumors.Cancer transcriptome profiling at the juncture of clinical translation.Chromosomal instability drives metastasis through a cytosolic DNA response.Precision oncology in the age of integrative genomics.Coexisting genomic aberrations associated with lymph node metastasis in breast cancer.Tracking Cancer Evolution Reveals Constrained Routes to Metastases: TRACERx Renal.Machine Learning Identifies Stemness Features Associated with Oncogenic Dedifferentiation.A novel BRCA2 mutation in prostate cancer sensitive to combined radiotherapy and androgen deprivation therapy.Efficacy of histology-agnostic and molecularly-driven HER2 inhibitors for refractory cancers.Men with a susceptibility to prostate cancer and the role of genetic based screening.Integrated genomic analysis identifies clinically relevant subtypes of renal clear cell carcinoma.Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets.Value-based genomics.Checkpoint suppressor 1 suppresses transcriptional activity of ERα and breast cancer cell proliferation via deacetylase SIRT1.Emergence of Intrahepatic Cholangiocarcinoma: How High-Throughput Technologies Expedite the Solutions for a Rare Cancer TypeMonoubiquitination of ASXLs controls the deubiquitinase activity of the tumor suppressor BAP1EMT- and stroma-related gene expression and resistance to PD-1 blockade in urothelial cancerCMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomasThe therapeutic significance of mutational signatures from DNA repair deficiency in cancer-3-Aminopropyl diazeniumdiolates suppress the progression of highly metastatic triple-negative breast cancer by inhibition of microvesicle formation nitric oxide-based epigenetic regulationCancer genomics: Human metastases under scrutinyMiPanda: A Resource for Analyzing and Visualizing Next-Generation Sequencing Transcriptomics Data
P2860
Q38636249-2BABE8F7-11BA-4AF1-8B34-C1070318735FQ41717791-4AB558DB-ED5E-41CE-B91F-9D9B04617954Q46007270-DE7C6146-7FC3-4CC8-A91B-CF01C6A83A61Q47094357-9BE655D1-DE3F-4ABD-9E0C-B51938A4B747Q47110361-2112DAB9-BE39-4AF7-9945-BB29A0CB4526Q47139668-4B29A8C2-F5F4-4CD8-990A-5795D6E8FD33Q47145371-28A5368A-47C2-4B2F-AC3C-F9D23198B077Q47161072-386DDC87-CC52-4DFE-B166-90B5278AA75AQ47177315-7A986613-7041-474B-AA45-F13D350D5D2AQ47236022-E4F89E56-AA37-48CA-A8B0-375514D04677Q47319640-238ACA46-4BA7-4514-B4D0-30FA97CB32BDQ48139301-8BDE409B-75A4-40AE-B6F9-E95313C5D73BQ49167508-686CC379-2483-4757-A8E5-AA1466C2A848Q49207442-A813031F-DE20-44CA-98A9-24CBA623A971Q49566680-28D2F1E8-AD0B-4180-B3AC-F05C1D2562DEQ50001777-B6953391-78F1-4D63-B1DC-2CC8FA70325BQ50105699-53CF0D7D-4303-4C21-8AD4-286C51152FDBQ51732792-FBE0E533-5AD3-40EA-B00F-D1535F6481C3Q52321029-42184F03-0E1E-49D7-830B-687094607D66Q52602401-CE53197A-355F-4FF8-9B07-DCCC53633C9AQ52630405-BE8DBF38-5E1A-466F-A48D-C5D01072CB58Q52668202-71DA4913-BC71-44BB-B5A1-E27F8AAE0A8FQ53423427-8C2BB130-84BE-4503-8ADC-07B89F12BF73Q53435219-D74BD954-29A1-4FB4-81B4-2D3DFFE1198DQ53684285-1A256450-BE6B-4F0A-A214-7D31571C404FQ55339672-1DB924D0-A4C0-4D0A-BED4-75F96ED5082BQ55367849-DA731937-B647-4448-9685-6F36066FF4A6Q57111762-5160B957-54FE-4327-BBA9-88CE617FBBADQ57804762-7FBEFB6E-A05D-4A69-AF56-3E8FF5C24CD6Q58695604-8B4ABFFA-859A-4487-8B38-D717650C3240Q58766544-722F2FB4-91F7-439B-9B29-518B22E39A4FQ58771249-6C321F36-FE27-439C-B37B-BEA9670C62B6Q58800928-C473FB3A-0EA5-4DA2-86E1-F029DB1810C8Q59087597-1DFEDCE6-390F-4B83-85AE-E7858F933C0AQ59127747-A98A899C-96B7-43D3-BEBE-27A521508924
P2860
description
2017 nî lūn-bûn
@nan
2017年の論文
@ja
2017年学术文章
@wuu
2017年学术文章
@zh
2017年学术文章
@zh-cn
2017年学术文章
@zh-hans
2017年学术文章
@zh-my
2017年学术文章
@zh-sg
2017年學術文章
@yue
2017年學術文章
@zh-hant
name
Integrative clinical genomics of metastatic cancer.
@en
Integrative clinical genomics of metastatic cancer.
@nl
type
label
Integrative clinical genomics of metastatic cancer.
@en
Integrative clinical genomics of metastatic cancer.
@nl
prefLabel
Integrative clinical genomics of metastatic cancer.
@en
Integrative clinical genomics of metastatic cancer.
@nl
P2093
P2860
P356
P1433
P1476
Integrative clinical genomics of metastatic cancer.
@en
P2093
Ajjai Alva
Ann F Schott
Arul M Chinnaiyan
Chandan Kumar-Sinha
Dan R Robinson
Daniel F Hayes
David C Smith
David Lucas
Elena M Stoffel
Erica Rabban
P2860
P2888
P304
P356
10.1038/NATURE23306
P407
P577
2017-08-02T00:00:00Z